Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic targetMelanie Weingart, Eric H. Raabe, Jacquelyn J. Roth et al.|Oncotarget|2014Cited by 85
DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with <i>In Silico</i> Analysis to Identify Novel Therapeutic TargetsAllison R. Hanaford, Eric H. Raabe, Tenley C. Archer et al.|Clinical Cancer Research|2016Cited by 68
Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-NorleucineSabrina Wang, Jeffrey Rubens, Brad Poore et al.|Clinical Cancer Research|2019Cited by 34
Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatinBrad Poore, Eric H. Raabe, Ming Yuan et al.|Neuro-Oncology|2018Cited by 28
The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicityJeffrey Rubens, Eric H. Raabe, Sabrina Wang et al.|Neuro-Oncology|2017Cited by 23